Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Inclusion Criteria

• •Participants with moderate-to-severe plaque psoriasis:
• •1. Deemed by the Investigator to be a candidate for phototherapy or systemic treatment for psoriasis, including ustekinumab;
• •2. Have at least 1 of the following cardiovascular risk factors:
• •Current cigarette smoker
• •Diagnosis of hypertension
• •Diagnosis of hyperlipidemia
• •Diabetes mellitus type 1 or 2
• •History of one or more of the following cardiovascular events: Coronary intervention (PCI) or coronary artery bypass grafting (CABG), myocardial infarction (heart attack), cardiac arrest, hospitalization for unstable angina, acute coronary syndrome, stroke, or transient ischemic attack
• •Obesity
• •Family history of premature coronary heart disease or sudden death in a first-degree male relative younger than 55 years of age or in a first-degree female relative younger than 65 years of age.